TY - JOUR
T1 - Analysis of computational tumor-infiltrating lymphocytes in breast cancer from the results of the TIGER challenge
AU - Rijthoven, Mart van
AU - Aswolinskiy, Witali
AU - Tessier, Leslie
AU - Salgado, Roberto
AU - van der Laak, Jeroen
AU - TIGER consortium
AU - Ciompi, Francesco
A2 - Lænkholm, Anne-Vibeke
A2 - Stovgaard, Elisabeth Specht
N1 - © 2026. The Author(s).
PY - 2026/5/15
Y1 - 2026/5/15
N2 - Tumor-infiltrating lymphocytes (TILs) is a recognized prognostic biomarker in breast cancer. However, poor interobserver agreement and limited reproducibility highlight the need for computational approaches. Despite advances, adoption of computational models has been hindered by lack of standardized methods and robust benchmarks. To address this, we launched TIGER, an international competition to build open-source computational TILs (cTILs) models. Here, we present a multi-centric analysis of cTILs methods on resections and biopsies from 3,708 human epidermal growth factor receptor 2-positive (HER2+) or triple-negative breast cancers (TNBC) from clinical practice and phase 3 trials. We report benchmarks on image analysis performance, show strong agreement of cTILs with pathologists, and demonstrate positive association of cTILs with neoadjuvant therapy response in HER2+, superior to visually scored TILs. We also show that cTILs add independent prognostic information to clinical variables in TNBC resections. Data, methods and benchmarks are publicly available: https://tiger.grand-challenge.org/ .
AB - Tumor-infiltrating lymphocytes (TILs) is a recognized prognostic biomarker in breast cancer. However, poor interobserver agreement and limited reproducibility highlight the need for computational approaches. Despite advances, adoption of computational models has been hindered by lack of standardized methods and robust benchmarks. To address this, we launched TIGER, an international competition to build open-source computational TILs (cTILs) models. Here, we present a multi-centric analysis of cTILs methods on resections and biopsies from 3,708 human epidermal growth factor receptor 2-positive (HER2+) or triple-negative breast cancers (TNBC) from clinical practice and phase 3 trials. We report benchmarks on image analysis performance, show strong agreement of cTILs with pathologists, and demonstrate positive association of cTILs with neoadjuvant therapy response in HER2+, superior to visually scored TILs. We also show that cTILs add independent prognostic information to clinical variables in TNBC resections. Data, methods and benchmarks are publicly available: https://tiger.grand-challenge.org/ .
KW - Humans
KW - Lymphocytes, Tumor-Infiltrating/immunology
KW - Female
KW - Breast Neoplasms/immunology
KW - Triple Negative Breast Neoplasms/pathology
KW - Prognosis
KW - Erb-b2 Receptor Tyrosine Kinases/metabolism
KW - Neoadjuvant Therapy
UR - https://www.scopus.com/pages/publications/105044893107
U2 - 10.1038/s41467-026-72956-x
DO - 10.1038/s41467-026-72956-x
M3 - Journal article
C2 - 42140903
SN - 2041-1722
VL - 17
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 6480
ER -